“The worried well” is a common marketing label and a poor way to describe people considering coronary artery calcium scoring. Some are anxious. Some have family history or risk uncertainty. Some encountered the test through a clinician; others saw a low-price scan ad. The marketing should not exploit concern or dismiss it.
The responsible role of CAC content is to explain a selective clinical decision: what the scan measures, when current guidance says it may inform risk assessment, what it cannot establish, and how results will be interpreted and followed.
This article addresses marketing, not medical advice. A qualified cardiology team must own clinical eligibility, content accuracy, result interpretation, and referral protocols.
Do not turn selective use into universal screening
The 2026 multisociety dyslipidemia guideline uses contemporary risk estimation and describes possible reclassification through selective CAC use. Its summary identifies age ranges and contexts in which CAC can improve risk assessment and guide lipid goals. That is not the same as “everyone over 40 needs a scan.”
The USPSTF’s 2018 statement found insufficient evidence to assess the balance of benefits and harms of adding CAC to traditional risk assessment in asymptomatic adults to prevent cardiovascular events; the topic is now being updated. Those sources answer different questions and may change. Clinical reviewers should verify the current guideline, recommendation status, and intended population at publication.
Marketing should say “may help refine a risk discussion for selected people” when that accurately reflects the service. Avoid fear-led claims such as “the test that could save your life” or guarantees that a zero score means no risk.
Explain what happens after the number
A scan without an interpretation pathway is a product, not a preventive-care service. The page should state who determines appropriateness, who reads the study, how results are communicated, whether incidental findings are handled, which clinician discusses next steps, and what the patient should do if they already have symptoms.
Do not route acute symptoms into a self-pay screening funnel. Provide appropriate emergency language approved by clinicians. Do not let a scheduling form imply that the website has assessed risk.
This need for a complete answer reflects the broader shift in healthcare search across Google and AI: patients need a coherent passage and a usable next step, not a page built around one high-volume phrase.
A worked page: the $99 scan offer
Imagine an imaging center advertising “Know your heart risk for $99—no referral needed.” The page shows a dramatic artery graphic and a green-zero/red-high score scale. It does not explain eligibility, limitations, radiation, interpretation, incidental findings, or what happens afterward.
The price may be accurate, but the complete impression is that one inexpensive scan delivers a definitive risk answer. The practice rebuilds the page around a clinician-approved decision. It explains the purpose and limits, identifies who may be considered under its protocol, distinguishes screening from evaluation of symptoms, states the self-pay price and inclusions, and describes result review and follow-up.
The call to action becomes “Check whether CAC assessment fits your risk discussion,” not “Get your score today.” If direct scheduling is clinically appropriate, the pre-scan process still verifies eligibility.
Make risk communication usable
Avoid presenting CAC as a verdict. Explain that a score is considered with other health information and that interpretation depends on the individual. Do not translate a numerical category into a treatment recommendation in generic marketing copy.
Visuals should help patients understand the pathway: risk assessment, possible scan, result interpretation, and shared next step. A fear-heavy image of a “widowmaker” artery may draw clicks while distorting the decision. Clinical reviewers should approve labels, ranges, and caveats in every infographic.
Replace healthcare marketing clichés such as “peace of mind” with specific information. A result may reduce uncertainty for some people and create new questions for others.
Price and access need context
Transparent pricing can be useful, especially where insurance coverage varies. State what the price includes, whether professional interpretation is separate, whether additional visits may be billed, and how current terms are confirmed. Do not imply that low cost eliminates clinical or financial tradeoffs.
Paid search should use the connected discipline in medical-practice Google Ads. Query intent, landing-page message, scheduling, clinical qualification, and privacy-safe measurement belong in one system. Google’s health-sensitive targeting policies and applicable privacy laws require separate review.
Advertising claims need their own evidence
The FTC evaluates both express and implied health claims and expects appropriate scientific support. A guideline citation does not authorize broader claims than the guideline makes. “Detects heart disease early,” “prevents heart attacks,” and “the most accurate test” each create different evidence and interpretation problems.
Keep a claim file with the exact wording, implied message, cited source, population, limitations, clinical approval, legal approval where warranted, and review date. Do not let an old landing page outlive a changed recommendation.
Market the conversation, not the scan
CAC scoring may be useful within an appropriately selected risk discussion. Its value does not come from making the number emotionally irresistible or turning uncertainty into urgency.
The strongest marketing makes the pathway visible: who the service may help, what the test can and cannot add, how the result will be interpreted, and where the patient goes next. When content respects those boundaries, the scan becomes part of care rather than a standalone product sold to anxiety.
Primary sources
Questions this article answers
Should a CAC scan be marketed to every adult?
No. Current professional guidance describes selective use in risk assessment, while the USPSTF evidence review is being updated. Eligibility and interpretation require clinician judgment.
Can a practice call a calcium score a 'heart-health report card'?
That shorthand can overstate what one test establishes. Content should explain what CAC measures, what it does not measure, and how the result may fit a broader risk discussion.
Should pricing be the lead message?
Transparent self-pay information can reduce uncertainty, but a low price should not imply that a scan is appropriate or harmless for everyone. The clinical pathway should remain clear.
Part of the Becoming the Clear Choice collection
Positioning, proof, content, and patient psychology for practices that need to create preference rather than mere awareness.
Explore the topic hub